Sangamo BioSciences Inc.

Drug Discovery; Molecular Diagnostics. Sangamo BioSciences' zinc finger DNA-binding proteins can be rationally designed to bind to any DNA sequence, and may have several commercially useful applications; production of human therapeutics, functional genomics and gene diagnostics.

Suppose you could just point a finger at a gene you wanted to turn on or turn off. That's basically what Sangamo BioSciences Inc. has shown they can do with their engineered zinc finger proteins that can be rationally designed to bind to any DNA sequence. The company calls the platform technology Uniform Gene Recognition (UGR) and is developing it into three broad commercial categories: Universal Gene Regulation for producing human therapeutics, Universal GeneTools for use in functional genomics research, and Universal Gene Identification for gene diagnostics.

Zinc finger DNA-binding proteins are transcription factors that recognize specific DNA base pair sequences based upon a set of "recognition...

More from Archive

More from Scrip

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.